Celeras Dx has developed an entirely new multiplex technology based upon the principle of microarrays. The hybcell – the only cylindrical microarray available throughout the world – delivers speedy and reliable results with minimal hands-on.
On the hybcell's surface antibodies are immobilised on a cylindrical coated surface. The sample is pipetted into the hybcell. The device - the hyborg - processes the tests completely autonomous. Matching antigens in the sample bind to these probes on the surface. A fluorescence readout shows these interactions.
Multiplexed hybcell immuno-tests provide quantitative evidence of up to 200 parameters - which might all be relevant for the same clinical diagnose - from a minimal amount of sample. Therefore these tests are well suited for monitoring over a longer period of time or broad screenings of different samples (blood, urine, serum, saliva).
The tests are based upon the principle of the proprietary compact profiling. It is the only technology that combines a competitive biomarker assay with a sandwich biomarker format. Therefore, different target concentrations (e.g mg/mL vs. ng/mL) for different biomarkers can be combined in a single test. The user pipettes the sample liquid (e.g. 100µL of whole blood) into the hybcell (cartridge), feeds the hyborg (instrument) with the hybcells and starts the test run.
at MISK Global Forum in Riyadh, Saudi Arabia (12-14 November, 2019).
at DxPx Conference in Duesseldorf, Germany (18 November, 2019).
at ECCMID in Paris, France (18-21 April, 2019).
Celeras Dx - Part of Cube Dx GmbH | Westbahnstrasse 55 | 4300 St. Valentin (Austria) | firstname.lastname@example.org